Atara Biotherapeutics (ATRA) Total Current Liabilities (2013 - 2026)
Atara Biotherapeutics' (ATRA) quarterly Total Current Liabilities came in at $5.6 million in Q1 2026, down 88.21% YoY from $47.9 million in Q1 2025, and down 62.17% on a QoQ basis from $14.9 million in Q4 2025.
Atara Biotherapeutics (ATRA) Total Current Liabilities (2013 - 2026) Analysis & Trends
Atara Biotherapeutics (ATRA) has 14 years of Total Current Liabilities data on file, last reported at $5.6 million in Q1 2026.
- Quarterly Total Current Liabilities fell 88.21% year-over-year to $5.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $5.6 million (down 88.21% YoY) and the FY2025 annual result came in at $14.9 million, down 88.91% from the prior year.
- Total Current Liabilities slipped to $5.6 million in Q1 2026, from $14.9 million in the prior quarter.
- In the past five years, Total Current Liabilities ranged from a high of $180.7 million in Q1 2024 to a low of $5.6 million in Q1 2026.
- A 5-year average of $82.5 million and a median of $74.6 million in 2023 frame the typical range for Total Current Liabilities.
- Annual changes were most pronounced in 2024 — Total Current Liabilities soared 166.21% — and 2025, when it sank 90.18%.
- Tracing ATRA's Total Current Liabilities over 5 years: stood at $78.9 million in 2022, then jumped by 80.22% to $142.2 million in 2023, then dropped by 5.38% to $134.6 million in 2024, then sank by 88.91% to $14.9 million in 2025, then plunged by 62.17% to $5.6 million in 2026.
- The last three Total Current Liabilities figures came in at $5.6 million (Q1 2026), $14.9 million (Q4 2025), and $18.1 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.47 Bn | 131.61 Bn | 2.84 Bn | 3.94 Bn |
| 2 | Regeneron Pharmaceuticals | 86.36 Bn | 78.37 Bn | 3.93 Bn | 5.53 Bn |
| 3 | Argenx Se | 65.16 Bn | 59.98 Bn | 1.37 Bn | 1.58 Bn |
| 4 | Moderna | 58.99 Bn | 53.85 Bn | 52.00 Mn | 2.53 Bn |
| 5 | BeOne Medicines | 42.08 Bn | 36.98 Bn | 1.53 Bn | 2.12 Bn |
| 6 | Alnylam Pharmaceuticals | 31.74 Bn | 28.43 Bn | 992.69 Mn | 1.51 Bn |
| 7 | BioNTech SE | 28.01 Bn | 9.61 Bn | 668.28 Mn | 2.49 Bn |
| 8 | Insmed | 27.50 Bn | 26.34 Bn | 358.27 Mn | 438.74 Mn |
| 9 | Royalty Pharma | 27.28 Bn | 26.45 Bn | - | 630.93 Mn |
| 10 | Atara Biotherapeutics | 143.57 Mn | 127.01 Mn | 439,000.00 | 6.85 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 6.85 Mn |
| Mar 31, 2026 | 5.65 Mn |
| Dec 31, 2025 | 14.92 Mn |
| Sep 30, 2025 | 18.06 Mn |
| Jun 30, 2025 | 14.56 Mn |
| Mar 31, 2025 | 47.89 Mn |
| Dec 31, 2024 | 134.57 Mn |
| Sep 30, 2024 | 155.98 Mn |
| Jun 30, 2024 | 148.27 Mn |
| Mar 31, 2024 | 180.69 Mn |
| Dec 31, 2023 | 142.23 Mn |
| Sep 30, 2023 | 79.09 Mn |
| Jun 30, 2023 | 74.55 Mn |
| Mar 31, 2023 | 67.88 Mn |
| Dec 31, 2022 | 78.92 Mn |
| Sep 30, 2022 | 72.24 Mn |
| Jun 30, 2022 | 65.69 Mn |
| Mar 31, 2022 | 101.56 Mn |
| Dec 31, 2021 | 105.79 Mn |
| Sep 30, 2021 | 86.15 Mn |